| |
Overall survival
|
Progression-free survival
|
|---|
|
Lead Author, Year
|
N
|
UPSC/clear cell/mixed
|
Deaths
|
3-years OS
|
Median follow-up (months)
|
N
|
Recur, progression or death (N)
|
3-years PFS
|
|---|
|
Gehrig, 2004 [25]
|
9
|
100 %/0 %/0 %
|
0
|
100 %
|
38
|
N/A
|
1
|
N/A
|
|
aLupe, 2007 [26]
|
33
|
33 %/9 %/15 %
|
13
|
55 % (2-years)
|
21
|
33
|
14
|
55 % (2-years)
|
|
Secord, 2007 [27]
|
51
|
N/A
|
5
|
91 %
|
36
|
51
|
13
|
69 %
|
|
aFields, 2008 [28]
|
30
|
100 %/0 %/0 %
|
10
|
52 %
|
N/A
|
29
|
12
|
54 %
|
|
aLupe, 2009 [16]
|
43
|
35 %/7 %/14 %
|
14
|
68 %
|
30
|
41
|
35
|
53 %
|
|
Secord, 2009 [29]
|
45
|
13 %/4 %/29 %
|
7
|
88 %
|
36
|
45
|
11
|
69 %
|
|
Geller, 2010 [17]
|
23
|
52 %/4 %/0 %
|
3
|
88 %
|
44
|
23
|
5
|
80 %
|
|
aGeller, 2011 [4]
|
41
|
9 %/NA/2 %
|
7
|
90 %
|
28
|
39
|
11
|
71 %
|
|
Abaid, 2012 [5]
|
32
|
13 %/9 %/9 %
|
3
|
N/A
|
19
|
8
|
8
|
84 %
|
|
aEinstein, 2012 [6]
| |
100 %/0 %0 %
| |
84 % (early stage); 50 % (advanced stage)
|
9
|
20
|
20
|
N/A
|
|
Dogan, 2013 [7]
|
11
|
18 %/18 %/0 %
|
0
|
N/A
|
18
|
1
|
5
|
N/A
|
|
Lan, 2013 [30]
|
35
|
N/A
|
4
|
82 %
|
36
|
35
|
9
|
62 %
|
|
aGeller, 2011 - updated
|
41
|
9 %/NA/2 %
|
15
|
75 %
|
60
|
39
|
15
|
71 %
|
-
UPSC uterine papillary serous carcinoma, PFS progression-free survival
-
aProspective study
